Advertisement

FLAER Based Assay According to Newer Guidelines Increases Sensitivity of PNH Clone Detection

  • Prabhu Manivannan
  • Seema TyagiEmail author
  • Hara Prasad Pati
  • Renu Saxena
Original Article
  • 12 Downloads

Abstract

Flow cytometry has become ‘gold standard’ for detecting abnormal clones in paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia (AA) and myelodysplastic syndrome (MDS). This pilot study was conducted in 2015 with a primary aim to evaluate the utility of single tube fluorescent aerolysin (FLAER) based testing and its comparison with two tubes non-FLAER based testing (CD55, CD59, CD24 and CD66b) in detecting abnormal PNH clones in these newly diagnosed cases. The secondary aim was an attempt to distinguish PNH from AA/MDS cases associated with PNH clones based on clinical, laboratory features and clone size at diagnosis. In this study, the abnormal PNH clones were detected using a single tube FLAER based testing and two tubes non-FLAER based testing in all cases of PNH (n = 12), healthy subjects (n = 18) and AA/MDS with PNH clone (n = 9) and compared with clinical and laboratory features at diagnosis. The receiver operator curve (ROC) analysis defined the optimal cut-offs for FLAER in granulocytes (> 0.7%) and monocytes (> 0.9%). There was significant positive correlation between FLAER and non-FLAER based testing in these cells (r > 0.3 and p < 0.05). FLAER based testing helped us in picking up smaller clones which were missed by latter technique in four patients thereby increasing its sensitivity and also technically proved to be cost-effective (Rs. 1800 vs. Rs. 2100). Even in PNH patients, the clone size was slightly higher by using FLAER when compared to non-FLAER based antibodies panel. The clone size of monocytes was always higher than granulocytes in both PNH and AA/MDS groups. Bone marrow cellularity and mean size of granulocytes and monocytes clone at diagnosis showed a striking statistically significant ‘p’ value of < 0.0001 between these groups. In this pilot study, a single tube FLAER based PNH testing had improved clone detection in all cases of PNH, AA/MDS with PNH clones. The clone size was > 30% in majority of PNH cases whereas in AA/MDS, it was usually < 10% at diagnosis. Hence this newer technique not only increased the sensitivity of PNH clone detection but also proved to be cost-effective.

Keywords

FLAER Paroxysmal nocturnal hemoglobinuria Aplastic anemia Myelodysplastic syndrome 

Notes

Acknowledgements

We thank “Indian Society of Hematology and Blood Transfusion” for funding Rs. 50,000/– Grant for this study.

Funding

Funding was provided by HERS and Indian Society of Hematology and Blood Transfusion (Grant No. IESC/T-161/02.05.2014).

Compliance with Ethical Standards

Conflict of interest

The author declares that they have no conflict of interest.

References

  1. 1.
    Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA (2005) PIG-A mutations in normal hematopoiesis. Blood 105:3848–3854CrossRefGoogle Scholar
  2. 2.
    Brodsky RA (2008) Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 22:65–74CrossRefGoogle Scholar
  3. 3.
    Madkaikar M, Gupta M, Jijina F, Ghosh K (2009) Paroxysmal nocturnal haemoglobinuria: diagnostic tests, advantages, and limitations. Er J Hematol 83:503–511CrossRefGoogle Scholar
  4. 4.
    Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E et al (2007) Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom 72:167–177CrossRefGoogle Scholar
  5. 5.
    Manivannan P, Ahuja A, Pati HP (2017) Diagnosis of paroxysmal nocturnal hemoglobinuria: recent advances. Indian J Hematol Blood Transfus 33:453–462CrossRefGoogle Scholar
  6. 6.
    Richards SJ, Hill A, Hillmen P (2007) Recent advances in the diagnosis, monitoring and management of patients with paroxysmal nocturnal haemoglobinuria. Cytom B Clin Cytom 72:291–298CrossRefGoogle Scholar
  7. 7.
    The International Agranulocytosis and Aplastic Anaemia Study (IAAAS) (1987) Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood 70:1718–1721CrossRefGoogle Scholar
  8. 8.
    Brunning RD, Orazi A, Germing U, Beau MM, Porwit A, Baumann I et al (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissue, 4th edn. IARC Press, Lyon, pp 88–93Google Scholar
  9. 9.
    Borowitz MJ, Craig FE, DiGuiseppe JA, Illingworth AJ, Rosse W, Sutherland DR et al (2010) On behalf of the Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom B Clin Cytom 78:211–230Google Scholar
  10. 10.
    Brodsky RA, Mukhina G, Li S, Nelson K, Chiurazzi PL, Buckley T et al (2000) Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using florescent aerolysin. Am J Clin Pathol 114:459–466CrossRefGoogle Scholar
  11. 11.
    Peghini PE, Fehr J (2005) Clinical evaluation of an aerolysin-based screening test for paroxysmal nocturnal hemoglobinuria. Cytom B Clin Cytom B 67:13–18CrossRefGoogle Scholar
  12. 12.
    Agarwal R, Chapple P, Brown M, Szer J, Juneja S (2015) Analysis of abnormal clones by the fluorescent aerolysin method in paroxysmal nocturnal haemoglobinuria andother marrow disorders. Int J Lab Hematol 37:14–21CrossRefGoogle Scholar
  13. 13.
    Sachdeva MU, Varma N, Chandra D, Bose P, Malhotra P, Varma S (2015) Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia. Ann Hematol 94:721–728CrossRefGoogle Scholar
  14. 14.
    Sutherland R, Keeney M, Illingworth A (2012) Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytom B Clin Cytom 82:195–208CrossRefGoogle Scholar
  15. 15.
    Illingworth A, Marinov I, Sutherland DR, Wagner-Ballon O, DelVecchio L (2018) ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related Disorders Part 3: data analysis, reporting and case studies. Cytom Part B 94B:49–66CrossRefGoogle Scholar
  16. 16.
    Hernandez-Campo PM, Almeida J, Sanchez ML, Malvezzi M, Orfao A (2006) Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 70:71–81CrossRefGoogle Scholar
  17. 17.
    Navenot JM, Muller JY, Blanchard D (1998) Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion 38:337–342CrossRefGoogle Scholar
  18. 18.
    Gupta PK, Charan VD, Kumar H (2009) PNH revisited: clinical profile, laboratory diagnosis and follow up. Indian J Pathol Microbiol 52:38–41CrossRefGoogle Scholar
  19. 19.
    Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M et al (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112:3099–3106CrossRefGoogle Scholar
  20. 20.
    Mayo VM, Mukhina GL, Garrett ES, Brodsky RA (2004) Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. Br J Haematol 126:133–138CrossRefGoogle Scholar
  21. 21.
    Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M et al (2009) Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 94:29–37CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of PathologyJIPMERPuducherryIndia
  2. 2.Department of HematologyAll India Institute of Medical Sciences (AIIMS)New DelhiIndia

Personalised recommendations